"Dr. Galsky On Neoadjuvant Immune Checkpoint Blockade In Bladder Cancer"
Matthew Galsky, MD, professor of medicine, urology, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai, discusses neoadjuvant immune checkpoint inhibition in patients with bladder cancer. Historically, chemotherapy has been the standard of care in the neoadjuvant setting, followed by cystectomy in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC). Two trials presented at the 2018 ASCO Meeting on neoadjuvant immune checkpoint blockade assessed either PD-1 or PD-L1 blockade in patients with MIBC. The only option for patients who are cisplatin-ineligible is surgery alone, Dr. Galsky said. Although single-arm studies are rarely practice changing, Dr. Galsky says that these studies will inform further studies that may transform care.
- Matthew Galsky, MD, Professor, Medicine, Hematology and Medical Oncology, Urology, Icahn School of Medicine at Mount Sinai